Our Stocks to Watch tomorrow include Grand Toys International Limited (NASD: GRIN), ProtoKinetix, Inc. (OTCBB: PKTX), Mvive, Inc. (OTC: MVIV), Ariel Way, Inc. (OTCBB: AWYI), Franklin Mining, Inc. (OTC: FMNJ) and Carrington Laboratories, Inc. (OTCBB: CARN).
Visit http://www.otcpicks.com/ to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
GRAND TOYS INTERNATIONAL (NASD: GRIN)
"Up 224.61% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/GRIN.php
Grand Toys International Limited, through its Hong Kong, PRC and US operating subsidiaries, develops, manufactures and distributes toy and toy-related products throughout the world; prints and assembles books and specialty packaging; and develops and manufactures party goods. Additional information on Grand Toys can be found on its website at www.grand.com. Additional information on Hua Yang can be found on www.huayangprinting.com. Additional information on Kord can be found on www.kordparty.com. Additional information on IPI can be found on its website at http://www.intplay.com/.
GRIN News:
February 14 - Grand Toys Announces Intention to Acquire Wham-O Inc.
Grand Toys International Limited (NASD: GRIN) announced the signing of a term sheet to acquire 100% of Wham-O, Inc. ("Wham-O") from Cornerstone Strategic Management Limited, a company owned and controlled by Raylin Hsieh, the wife of Grand Toys major shareholder, Jeff Hsieh. As consideration for the proposed transaction, Grand Toys will pay to Cornerstone Strategic Management Limited cash consideration of US$35 million adjusted for liabilities of Wham-O and 100% of the shares of its wholly-owned subsidiaries Hua Yang Holdings Co., Ltd. ("Hua Yang") and Kord Holdings Inc. ("Kord"). The inter-company liabilities between (i) Grand Toys, and (ii) Hua Yang and Kord, will be written off at closing of the transaction. The transaction will be subject to due diligence, Board and shareholder approval, the successful completion of a convertible bond financing to fund the purchase price, the absence of any material adverse changes in Wham-O, the negotiation of satisfactory definitive documentation for the transaction, and the fulfillment of all conditions precedent to the transaction.
Based in the US, Wham-O is a leading manufacturer of branded outdoor and leisure products with annual turnover of approximately US$50 million in fiscal 2007 (unaudited). Wham-O designs, manufactures and markets some of the most recognizable brands in the world today, such as Frisbee®, Slip 'N Slide®, Hula Hoop®, Morey® Boogie® boards, Snow Boogie® and BZ® Pro Boards(TM). The proposed acquisition of Wham-O will give Grand Toys a platform on which to build a world-class branded outdoor products, leisure products and specialty toy company with a suite of recognized brands that have significant potential for growth in international markets. Wham-O will give Grand Toys a core business to build around and allow it to drive synergies with International Playthings, Inc. ("IPI"), its wholly-owned sales and distribution business in the US. As a part of this proposed transaction, Grand Toys will divest its low margin, non-core Hua Yang and Kord manufacturing businesses. Grand Toys' strategy is to become a focused branded consumer outdoor products, leisure products and specialty toy company with a significant suite of recognized brands and proprietary nationwide US sales and distribution capabilities.
"The new Board of Directors of Grand Toys, which was assembled in mid-2007, has been focusing on developing a new direction and strategy for Grand Toys to give the company a platform for growth" comments David Howell, CFO of Grand Toys. "We believe the acquisition of Wham-O represents a transformational opportunity for Grand Toys and it will become the key asset around which we will build our business. In addition, the divestiture of the low margin, non- core Hua Yang and Kord manufacturing businesses frees up significant working capital for the company and allows us to reduce substantially our bank debt, creating a much healthier balance sheet."
A Special Committee of the Board has been formed to oversee the transaction and the Special Committee will be delivering a recommendation to the shareholders. Latitude Capital Group, an Asian investment banking firm, has been appointed to arrange the acquisition financing for the company. Jones Day, an international law firm, has been appointed to represent the company on the transaction.
ABOUT WHAM-O INC.
Founded in 1948, WHAM-O is headquartered in Emeryville, California. WHAM- O's leading toy brands include classic toys such as: the Slip 'N Slide® water slide, Frisbee® flying discs, Hula Hoop®, and Super Ball®. WHAM- O's leading outdoor, water, surf and snow recreational brands include: the Original Frisbee Disc® flying disc for use in freestyle, ultimate and disc golf, the Hacky Sack® footbag, MOREY® Boogie® bodyboards, and BZ® PRO BOARDS(TM) bodyboards, CHURCHILL® swimfins, SNOW BOOGIE® and SLEDZ® snow sleds and Riva Sports® snowboards. WHAM-O designs and manufactures a core of more than 70 products that appeal to all ages. For more information, visit www.wham-o.com or call toll free 1-888-WHAM-O-50 (1-888-942-6650).
PROTOKINETIX INCORPORATED (OTCBB: PKTX)
"Up 70.37% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/PKTX.php
ProtoKinetix Inc is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products. For more detailed information, visit www.protokinetix.com.
PKTX News:
February 13 - Edward D. Martin, M.D. Accepts Chair of ProtoKinetix' Business Advisory Board
Ross Senior, President and CEO of ProtoKinetix, Inc. (OTCBB: PKTX) announced the appointment of Edward D Martin, M.D. as Chairman of the Business Advisory Board. Dr. Martin has provided valuable advice to ProtoKinetix and has been instrumental in the introduction of AAGP™ to scientists and senior management in the health care industry. ProtoKinetix’ Board and management welcome the wealth of experience that Ed Martin brings to the Company’s future development.
Edward D. Martin, M.D. is the co-founder and Chairman of Martin, Blanck & Associates, Inc., a consulting firm to the health care industry, government, and to major health care information management and technology companies since March of 1998.
From July, 2000 through December, 2004, Dr. Martin was a Senior Vice President and the Chief Medical Officer at Science Applications International Corporation (SAIC) and continues to support SAIC on a part-time basis.
Dr. Martin had a distinguished 30-year career in public service as a commissioned officer in the United States Public Health Service, Department of Health and Human Services, (formerly Department of Health, Education and Welfare). His last assignments were at the Department of Defense (DoD) where he served as the Acting Assistant Secretary of Defense (Health Affairs), and, prior to this appointment, as Principal Deputy Assistant Secretary of Defense (Health Affairs). In the latter position, held from December 1992 to April 1997, Dr. Martin exercised day-to-day executive management and oversight of all Department of Defense (DoD) health policies, programs, and activities within the Military Health System (MHS). The Nation’s second largest health care system, the MHS, delivers care to over 9 million beneficiaries through a worldwide network of more than 500 hospitals and clinics, and provides military beneficiaries with a triple-option health program.
In his two terms as Acting Assistant Secretary of Defense for Health Affairs, from January 1993 to March 1994, and from March 1997 until March 1998, respectively, Dr. Martin assumed responsibility for the overall supervision of the health and medical affairs of the DoD. He also served as the Deputy Assistant Secretary of Defense (Professional Affairs and Quality Assurance) from March 1990 until December 1992.
Dr. Martin arrived at the Pentagon in 1989 after 15 years of executive leadership positions with the Public Health Service (PHS). He served as Chief of Staff for C. Everett Koop, M.D., Surgeon General; Director, Bureau of Health Care Delivery and Assistance; Acting Deputy Administrator, Health Resources and Services Administration; and Director, Bureau of Community Health Services. Dr. Martin was commissioned in the PHS in May 1975 and held the rank of Rear Admiral upon his retirement in April 1998.
A native of Topeka, Kansas, Dr. Martin served for 5 years as a United States Navy Hospital Corpsman prior to completing his undergraduate degree at the University of Kansas in 1966. He received his M.D. degree from the University of Kansas Medical School in 1970 and completed his residency in Pediatrics at the Montefiore Hospital and Medical Center in 1973.
Dr. Martin has written on topics ranging from rural health and primary care initiatives to quality of care. He is the recipient of numerous awards and honors, including two Public Health Service Distinguished Service Medals, the Defense Distinguished Service Medal, and the Secretary of Defense Medal for Meritorious Civilian Service.
Dr. Martin resides in Arlington, Virginia, with his wife, Kathleen, a retired Captain in the Public Health Service, and their two sons, James and William.
MVIVE INCORPORATED (OTC: MVIV)
"Up 83.33% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/MVIV.php
Toronto-based Mvive Inc., through its wholly owned subsidiary Mvive Media Group Inc., has become a founding member in the new mobile messaging revolution. As the need for information on the go increases exponentially, Mvive provides unique solutions to deliver rich content and multimedia services through the Internet and mobile devices. For more information, visit the company's Web site at http://www.mvive.com/.
MVIV News:
February 13 - Mvive Achieves Largest Delivery of Mobile Coupons in North America
Mvive, Inc. (OTC: MVIV)(Frankfurt: 4M1)(WKN: A0M5WL) announced that it has successfully delivered thousands of mobile coupons (Moupons™) for over 800 retailers with in excess of 1,000 locations during their beta test phase of implementation. Thousands of Moupons™ were downloaded onto cell phones for presentation to retailers with a 100% efficiency and success rate making this the largest successful delivery of mobile coupons by a single company, in North America.
A Moupons™ is a retail discount mobile coupon that can be downloaded from the internet onto a cell phone, Blackberry, etc. which can then be presented to the retailer on the customer's cell phone to obtain the advertised discount and completely eliminating the traditional paper flow and distribution of regular coupons. To achieve a broad base test and market exposure, the retailer group included everything from restaurants, clothing outlets and jewelry stores to book stores and fitness clubs.
"We were delighted with the resounding operational success of this live, real world technology test phase and even more ecstatic about the response we received from many of the retailers who could not say enough about the ease and efficiency with which the service worked," stated Mr. Roy Choi, President of Mvive. "As more and more content and content delivery is being sought out by companies such as Google and Research in Motion, etc., we at Mvive feel that our Moupons™ and the Moupon™ delivery system as well as future Mvive products and services, will be in great demand. We anticipate the Mvive registration process to commence in March, 2008."
ARIEL WAY INCORPORATED (OTCBB: AWYI)
"Up 44.44% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/AWYI.php
Ariel Way, Inc. operates as a technology and services company for global communications, multimedia, and digital signage solutions and technologies. It develops and deploys solutions for business television, digital signage, and interactive media delivered over a combination of satellite, terrestrial, and wireless local networks. The company's digital signage service includes technologies using LCD television and plasma screens to deliver video based messaging directly to consumer audiences. Its integrated multimedia services include music radio, video, and Internet protocol based file transfer for training/catalogs/point of sale integrated with other information to the clients. Ariel Way serves finance-oriented services companies primarily in United Kingdom. The company is headquartered in Vienna, Virginia.
AWYI News:
February 14 - Ariel Way, Inc. Completes Agreement to Acquire Syrei Holding UK, Ltd
Ariel Way, Inc. (OTCBB: AWYI) announced that, on February 13, 2008, the Company completed and signed the definitive Agreement and Plan of Merger to acquire Syrei Holding UK, Ltd, a UK and Sweden based telecom-consulting firm comprised of senior specialists and experts in the evolving global telecommunications market (http://www.syrei.com/). The transaction has a two-step closing process with a first expected closing within a few days, on or around February 19, 2008.
Arne Dunhem, Ariel Way president and CEO, said, “Many have been awaiting the news on the Syrei transaction. For various reasons, our signing of the agreement got delayed. We are truly excited with Syrei becoming part of Ariel Way. Syrei president Thomas Strangert's team of technical experts have over ten years successfully been providing and will continue to provide services worldwide to major corporations and telecom operators. They will also add global expertise to our strategy of building a state-of-the-art highly secure Digital Signage Network and will have primary focus on markets in Europe and Asia. We expect this acquisition to be immediately accretive to Ariel Way's earnings.”
Thomas Strangert, CEO of Syrei, said, “This transaction is a fascinating step for Syrei and we believe we can add a new strategic dimension to Ariel Way. We are excited about actively supporting the Digital Signage activities in Europe and Asia in addition to continue to expand our current customer base on a worldwide basis.”
Syrei, founded in 1997, is a telecom-consulting firm operating out of the UK and Sweden comprised of senior specialists and experts in the evolving global telecommunications market. Syrei's management and technical experts have successfully delivered professional services to value added service providers, telecom equipment manufactures and operators in more than 40 countries around the world. Syrei is a complete solution provider and a system integrator that is able to accept the total responsibility of large and complex projects. Syrei's consultants have been brought in to advise and aid major corporations and telecom operators like Ericsson, Nokia, 3GIS, ABB, Orange, SonyEricsson, Swedbank, Tele2, TeliaSonera, TIM etc.
FRANKLIN MINING INCORPORATED (OTC: FMNJ)
"Up 37.50% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/FMNJ.php
Franklin Mining, Inc., an exploration stage company, engages in the exploration, development, and mining of precious and nonferrous metals. It primarily focuses on gold, silver, tin, lead, copper, and zinc metals. The company has a joint venture contract with COMIBOL to develop and mine a section of the Cerro Rico Mine, known as the Palivairi project. It also owns 51% interest in the Pulacayo tailings project. In addition, Franklin Mining holds interests in the Franklin Mines located in Clear Creek County, Colorado; the Rio Grande GTL project located in Bolivia; and the Tierra Del Fuego gas industrialization project in Argentina. The company was founded in 1864. It was formerly known was WCM Capital, Inc. and changed its name to Franklin Mining, Inc. in 2003. Franklin Mining is based in Las Vegas, Nevada with additional offices in La Paz and Santa Cruz, Bolivia.
FMNJ News:
February 14 - Escala's Gold Reserves Projected to Be Greater Than Expected
Franklin Mining, Inc. (OTC: FMNJ) (Frankfurt: FMJ) CEO, William Petty, confirms that Franklin will begin taking gold from the first of its four known sources within their 500 hectare concession from COMIBOL.
The first mining specifically for gold will begin at the Cerro Blanco, the nearest of the four sites to where Franklin is presently mining silver, zinc and lead.
The initial discovery of gold at the Escala was made in early-1993. Within the year, a 70,000 square meter area at Cerro Blanco was gridded and 134 systematic samples returned an average 1.2 grams of gold per ton.
A series of 783 continuous and contiguous three meter chip samples were taken from within an approximate 35,000 square meter area after bulldozer benching and diamond drilling. This second set of samples confirmed earlier results. Gold mineralization was strongly zoned and contained significant sections above 1.0 grams per ton. The average of 60% of all samples was 0.51 gram per ton; the average of the remaining 40% was 1.16 grams per ton. At the highest end of the range of all assay results, there were a few as high as 2.8 and 3.9 grams per ton.
Additional information on Franklin's plans for mining at the Escala is available at http://www.franklinmining.com/, specifically in multiple Letters from the President to be posted during February 2008.
ABOUT THE ESCALA MINE
Comprising three separate mining applications, COMIBOL's Escala Mine concession totals 2,000 hectares located in the Sud Lipez Province, near Bolivia's border with Argentina. Franklin Mining, Bolivia has been awarded a contract to mine 500 hectares within the original concession. Escala II and Escala III mining applications are currently assigned to another company.
The original Escala Mine was established during the Spanish colonial period and has been mined for lead, zinc, gold and silver. In 2007, Franklin Mining, Bolivia negotiated an agreement with COMIBOL, National Mining Company of Bolivia, to resume mining operations within the area of the original concession.
CARRINGTON LABS INCORPORATED (OTCBB: CARN)
"Up 27.50% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/CARN.php
Carrington Laboratories, Inc. operates as a research-based biopharmaceutical, medical device, raw materials, and nutraceutical company. It engages in the development, manufacture, and marketing of naturally-derived complex carbohydrates and other natural product therapeutics for the treatment of major illnesses, the dressing, and management of wounds and nutritional supplements. The company operates in two segments, Medical Services and Consumer Services. The Medical Services segment sells various wound and skin care medical products, and provides manufacturing services to customers in medical products markets. These products are primarily sold through sole source distributors, and marketed to hospitals, nursing homes, alternative care facilities, cancer centers, home healthcare providers, and managed care organizations. The Consumer Services segment sells and licenses consumer products and bulk raw materials in the consumer health and beauty care products markets. This segment also sells finished products, as well as provides product development and manufacturing services to customers in the cosmetic and nutraceutical markets. In addition, Carrington Laboratories, through its subsidiary, DelSite Biotechnologies, Inc., engages in the research, development, and marketing of its proprietary GelSite technology for controlled release and delivery of bioactive pharmaceutical ingredients. The company was founded in 1973 and is headquartered in Irving, Texas.
CARN News:
February 14 - Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
- Human Trials to Begin Later This Year
- Only Nasal Powder Bird Flu Vaccine Under Development
- Patient-Friendly (No Needles); No Preservatives
- Stable at Room Temperature For 3 Years; No Cold Chain Distribution Required
Carrington Laboratories, Inc. (OTCBB: CARN) announced that its wholly-owned subsidiary DelSite Biotechnologies, Inc. received a shipment of clinical-grade H5N1 (bird flu) antigen from a major pharmaceutical company to commence production, under cGMP requirements, of clinical quantities of DelSite's nasal powder bird flu (H5N1) vaccine. The nasal powder bird flu vaccine is scheduled to begin testing in a Phase I human clinical trial later this year.
The vaccine will utilize DelSite's proprietary GelVac(TM) nasal powder delivery platform, which offers many distinct advantages over traditional vaccine delivery systems: (1) easy, needle-free, self-administration, not requiring healthcare professionals; (2) enhanced protection because administration of vaccine into nasal cavity stimulates both a systemic response and mucosal response; (3) no adverse side effects caused by preservatives; (4) stability at room temperature, which eliminates the need for cold storage or cold chain distribution, thereby opening distribution to Third World countries where refrigeration is often not available; and, (5) a demonstrated shelf life of an influenza vaccine of three years, enabling potential stockpiling in the event of a pandemic.
As a prelude to the Phase I human trials, in January 2008 toxicology studies were successfully completed on a GelVac nasal powder (H5N1) influenza vaccine. The GelVac nasal powder platform has also successfully completed a Phase I safety study in which the delivery device provided a consistent, greater-than-90-percent delivery of the powder to the desired site in the nose.
Carlton E. Turner, PhD, Carrington's president and CEO, stated, "We are focusing our full attention on advancing DelSite's GelVac nasal powder delivery platform for vaccines and therapeutics, and the H5N1 bird flu antigen was selected specifically for this effort. We completed all toxicology studies last year and reported results in January 2008. Receiving the current shipment of the non-egg-based, clinical-grade bird flu antigen for human studies was the next step in our efforts. Our regulatory pathway has been determined with the FDA, and we intend to proceed with clarity of purpose to the Phase I safety and effectiveness human trial with the nasal powder bird flu vaccine later this year."
Dr. Turner added, "The success of Wyeth's Prevnar® pneumococcal vaccine and Merck's Gardasil® vaccine for cervical cancer has created a renewed interest in vaccines. According to a report by the Pharmaceutical Research and Manufacturers of America, more than 50 companies had 146 vaccines in various stages of development in 2007. Of these, 138 were classical liquid vaccines requiring needles, cold storage (2-8 degrees C), cold chain distribution (2-8 degrees C), and adjuvants and/or preservatives. Five were nasal mist vaccines with the same requirements except for needles, one was an influenza dermal patch, and two were powder formulations. Simply put, those requiring needles are not distributor- or user-friendly, and those requiring cold storage are not distributor- and may not be user-friendly."
"A simple, less expensive, easy-to-distribute, user-friendly delivery system would serve to complete the vaccine paradigm shift away from needles and cold storage/distribution as was started by FluMist®, a liquid nasal spray flu vaccine," Dr. Turner added. "Dr. Nayer Khazani, a specialist in internal medicine who also does research and teaches at Stanford University Medical Center, wrote in an article (February 2, 2008) in the San Francisco Chronicle, stating that ' ... as delivery systems move from needles to patches and nasal powders, prevention (and even cure) may come without the sting.' His comments underscore our belief that the GelVac nasal powder platform developed by DelSite will complete this total paradigm shift and, clearly, without a sting."
"GelVac(TM) powder has been shown to work with and stabilize many antigens and protein and peptide therapeutics," continued Turner. "All formulations tested are stable at room temperature, require no needles, no preservatives, no cold storage and can be shipped anywhere free of the restrictive cold chain distribution systems associated with other vaccines. As a nasal powder, it is patient-friendly and does not require administration by a medical professional. No painful injection could mean greater public acceptance and thus public protection on a broader scale against specific diseases."
"At the corporate level, we are analyzing our business models and exploring strategies to move all our business units forward. We have invested more than $54 million in DelSite and have incurred financial losses over recent years. As a company we are dedicated to funding DelSite's initiatives and programs. The fact that a major pharma company has twice provided us, free of cost, a non-egg based H5N1 bird flu antigen produced under the restriction required for human use, indicates that much of the heavy lifting may be behind us."
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com have been compensated thirteen thousand dollars by a third Party (Haynes Capital) for MVIV advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
